Literature DB >> 23021297

Effectiveness and pattern of use of continuation and maintenance electroconvulsive therapy.

Erika Martínez-Amorós1, Narcís Cardoner, Verònica Gálvez, Mikel Urretavizcaya.   

Abstract

Patients with major depressive disorder (MDD) who require an acute course of electroconvulsive therapy (ECT) have high relapse rates. Therefore, an effective maintenance treatment strategy needs to be established. Continuation and maintenance ECT (C/M-ECT) could be an adequate treatment option, although the lack of controlled studies has led to its usefulness being questioned. This review includes a detailed description of studies on the effectiveness/efficacy of ECT in MDD. Despite their methodological limitations, the results appear to support the idea that C/M-ECT would be a safe and effective alternative, especially in patients with severe and recurrent disease. Nevertheless, more controlled studies are needed to provide new evidence and allow a more accurate assessment of the efficacy, safety and pattern of use of C/M-ECT.
Copyright © 2012 SEP y SEPB. Published by Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23021297     DOI: 10.1016/j.rpsm.2012.06.004

Source DB:  PubMed          Journal:  Rev Psiquiatr Salud Ment        ISSN: 1888-9891            Impact factor:   3.318


  2 in total

1.  Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model.

Authors:  L Vallejo-Torres; I Castilla; N González; R Hunter; P Serrano-Pérez; L Perestelo-Pérez
Journal:  Psychol Med       Date:  2014-10-30       Impact factor: 7.723

2.  Practice of Acute and Maintenance Electroconvulsive Therapy in the Psychiatric Clinic of a University Hospital from Turkey: between 2007 and 2013.

Authors:  Melike Ceyhan Balci Sengul; Ayse Nur Inci Kenar; Ezgi Hanci; İbrahim Sendur; Cem Sengul; Hasan Herken
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-02-29       Impact factor: 2.582

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.